Diagnostic and therapeutic potentials of methyltransferase-like 3 in liver diseases.
Biomed Pharmacother
; 172: 116157, 2024 Mar.
Article
en En
| MEDLINE
| ID: mdl-38301420
ABSTRACT
Methyltransferase-like 3 (METTL3), a component of the RNA N6-methyladenosine (m6A) modification with a specific catalytic capacity, controls gene expression by actively regulating RNA splicing, nuclear export, stability, and translation, determines the fate of RNAs and assists in regulating biological processes. Studies conducted in recent decades have demonstrated the pivotal regulatory role of METTL3 in liver disorders, including hepatic lipid metabolism disorders, liver fibrosis, nonalcoholic steatohepatitis, and liver cancer. Although METTL3's roles in these diseases have been extensively investigated, the regulatory network of METTL3 and its potential applications remain unexplored. In this review, we provide a comprehensive overview of the roles and mechanisms of METTL3 implicated in these diseases, establish a regulatory network of METTL3, evaluate the potential for targeting METTL3 for diagnosis and treatment, and discuss avenues for future development and research. We found relatively upregulated expressions of METTL3 in these liver diseases, demonstrating its potential as a diagnostic biomarker and therapeutic target.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Enfermedad del Hígado Graso no Alcohólico
/
Neoplasias Hepáticas
Tipo de estudio:
Diagnostic_studies
Idioma:
En
Revista:
Biomed Pharmacother
Año:
2024
Tipo del documento:
Article